Xiaoyan Jiang

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 19

Top Venues

International journal of molecular sciences

Leukemia

Pharmaceutics

Nature cancer

University of British Columbia

McGill University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of British Columbia Jul 01 2013

Canada

Professor :: Department of Medical Genetics

BC Cancer Agency

Canada

Distinguished Scientist :: Terry Fox Laboratory

Shanghai Institute of Medical Genetics

China

Adjunct Professor :: School of Medicine

Shanghai Jiaotong University

China

Adjunct Professor

University of British Columbia

Canada

Associate Professor :: Department of Medical Genetics

University of British Columbia

Canada

Assistant Professor :: Department of Medical Genetics

Education History

McGill University

Canada

PHD

Publications

Andrew Wu, Xiaohu Liu, Clark Fruhstorfer, Xiaoyan Jiang
Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia. International journal of molecular sciences 25 (6) (2024)
Andrew Wu, Xiaohu Liu, Clark Fruhstorfer, Xiaoyan Jiang
Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia. International journal of molecular sciences 25 (6) (2024)
Gerry Krystal, Xiaoyan Jiang
Connie Eaves (1944-2024). Nature cancer (2024)
Andrew Wu, Xiaohu Liu, Clark Fruhstorfer, Xiaoyan Jiang
Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia. International journal of molecular sciences 25 (6) (2024)
Gerry Krystal, Xiaoyan Jiang
Connie Eaves (1944-2024). Nature cancer 5 (6) (2024)
Andrew Wu, Xiaohu Liu, Clark Fruhstorfer, Xiaoyan Jiang
Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia. International journal of molecular sciences 25 (6) (2024)
Andrew Wu, Kelly A Turner, Adrian Woolfson, Xiaoyan Jiang
The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia. Pharmaceutics 15 (3) (2023)
Andrew Wu, Kelly A Turner, Adrian Woolfson, Xiaoyan Jiang
The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia. Pharmaceutics 15 (3) (2023)
Andrew Wu, Kelly A Turner, Adrian Woolfson, Xiaoyan Jiang
The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia. Pharmaceutics 15 (3) (2023)
Andrew Wu, Ryan Yen, Sarah Grasedieck, Hanyang Lin, Helen Nakamoto, Donna L Forrest, Connie J Eaves, Xiaoyan Jiang
Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis. Leukemia (2023)
Ryan Yen, Sarah Grasedieck, Andrew Wu, Hanyang Lin, Jiechuang Su, Katharina Rothe, Helen Nakamoto, Donna L Forrest, Connie J Eaves, Xiaoyan Jiang
Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial. Leukemia 36 (10) (2022)
Xingjian Zhai, Xiaoyan Jiang
Properties of Leukemic Stem Cells in Regulating Drug Resistance in Acute and Chronic Myeloid Leukemias. Biomedicines 10 (8) (2022)
Aysha S Ansari, Remant Bahadur Kc, Xiaoyan Jiang, Hasan Uludağ
Investigation of water-insoluble hydrophobic polyethylenimines as RNAi vehicles in chronic myeloid leukemia therapy. Journal of biomedical materials research. Part A 109 (11) (2021)
Xiaojia Niu, Katharina Rothe, Min Chen, Sarah Grasedieck, Rick Li, Sung-Eun Nam, Xiuyan Zhang, German E Novakovskiy, Ye-Hyeon Ahn, Irina Maksakova, Shenshen Lai, Hong Zhang, Jun Yan, Hong Liu, Yun Zhao, Depei Wu, Yubin Ge, Wyeth W Wasserman, Arefeh Rouhi, Florian Kuchenbauer, Calvin K Yip, Zaihui Zhang, Xiaoyan Jiang
Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia. Blood 137 (26) (2021)
Andrew Wu, Xiaoyan Jiang
p21-Activated kinases as promising therapeutic targets in hematological malignancies. Leukemia (2021)
Damian Lai, Min Chen, Jiechuang Su, Xiaohu Liu, Katharina Rothe, Kaiji Hu, Donna L Forrest, Connie J Eaves, Gregg B Morin, Xiaoyan Jiang
Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia". Science translational medicine 11 (501) (2020)
Cally J Ho, Gayathri Samarasekera, Katharina Rothe, Jing Xu, Kevin C Yang, Emily Leung, Michelle Chan, Xiaoyan Jiang, Sharon M Gorski
Puncta intended: connecting the dots between autophagy and cell stress networks. Autophagy 17 (4) (2020)
Damian Lai, Min Chen, Jiechuang Su, Xiaohu Liu, Katharina Rothe, Kaiji Hu, Donna L Forrest, Connie J Eaves, Gregg B Morin, Xiaoyan Jiang
PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia. Science translational medicine 10 (427) (2019)
Katharina Rothe, Vanessa Porter, Xiaoyan Jiang
Current Outlook on Autophagy in Human Leukemia: Foe in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions. International journal of molecular sciences 20 (3) (2019)

Xiaoyan Jiang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Xiaoyan Jiang